SLC5A2 and hydrops fetalis: SGLT2 inhibitors, as well as having consistent and meaningful benefits on reducing the risk of worsening HF and mortality, reduce patient-reported symptoms and improve the degree of patient-reported functional limitation as assessed by the KCCQ.2,8,18–22 Two other trials have examined the effect of SGLT2 inhibition on accelerometer outcomes.